Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 9 Lymphoma, Non-Hodgkin 7 Recurrence 2 Lymphoma 2 Cytokine Release Syndrome 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Craniopharyngioma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Burkitt Lymphoma 1 Astrocytoma 1 Advanced Liver Cancers 1

Interventions

Cyclophosphamide 32 Vincristine 22 blinatumomab 20 Methotrexate 20 Specimen Handling 19 Prednisone 19 Cytarabine 17 merphos 16 prednylidene 15 deltacortene 15 Biopsy 15 Mercaptopurine 14 Doxorubicin 14 Dexamethasone 14 N,N-dicyclohexyl-isoborneol-10-sulfonamide 13 pegaspargase 12 azathiopurine 12 Rituximab 12 Etoposide 12 dexamethasone acetate 11 dexamethasone 21-phosphate 11 auricularum 11 Spinal Puncture 11 Calcium Dobesilate 11 Asparaginase 11 Leucovorin 10 fludarabine 9 Magnetic Resonance Spectroscopy 9 Inotuzumab Ozogamicin 9 Daunorubicin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × tocilizumab × 90 days × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡